glp-1 receptor agonist drugs in development research Glucagon-like peptide-1 receptor: mechanisms and advances therapy GLP-1 Agonists Market Report 2025-2033,

How do they work

Key Mechanisms of Action : GLP-1 Receptor Agonism (Activation): Similar to current weight-loss drugs, it mimics the GLP-1 hormone to increase satiety (feeling full) and reduce appetite

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

Limited head-to-head studies compare established glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is), and sodium-glucose co-transporter-2 inhibitors (SGLT-2is) to insulin in the management of uncontrolled type 2 diabetes mellitus (T2DM)

The problem is what the studies actually show.

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications that have gained significant attention in recent years for their ability to manage blood sugar levels and promote weight loss